Law360, San Francisco (May 10, 2011, 7:07 PM ET) -- A group of pharmacies urged the Ninth Circuit on Tuesday to reinstate its challenge to Pfizer Inc.’s $68 billion merger with Wyeth, arguing the deal has resulted in higher prices and the loss of innovation.
The pharmacies in the long-running case claim the deal — which was completed in 2009 — ran afoul of Section 7 of the Clayton Act and Section 1 of the Sherman Act because Pfizer and Wyeth directly competed with each other in various submarkets of the overall pharmaceutical market.
Joseph Alioto...
Pharmacies Attack $68B Pfizer-Wyeth Deal In 9th Circ.
To view the full article, take a free trial now.
